ArticleBone research2026
Inhibition of cyclin-dependent kinase 8 modulates chondrocyte transition to hypertrophy and provides in vivo protection against spontaneous osteoarthritis.
Article in Bone research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chondrocyte hypertrophy is a key hallmark of osteoarthritis (OA) that drives a multitude of whole-joint disease processes. There are no approved disease-modifying pharmaceuticals in clinical use, emphasising the urgent need for innovative therapeutics. Screening of a focussed chemical library using a novel in vitro platform discovered that inhibition of CDK8/19 mediator kinases modulated chondrocyte behaviours with potential to limit OA hallmarks. Transcriptomic analysis of various chondrogenic cell populations revealed that CDK8/19-inhibitor treatment upregulated pro-anabolic/anti-catabolic markers, downregulated markers of hypertrophy and protected from IL1β-induced extracellular matrix degradation. CDK8 was also found to be upregulated in chondrocytes in vitro following IL1β stimulation. This translated to human OA cartilage, where CDK8, MED12 and pSTAT1 were found to co-localise to cartilage lesions. Exposure to CDK8/19-inhibitor modified cell metabolism in hypertrophic chondrocytes and reduced inflammatory processes in THP-1-derived macrophages. CDK8/19-inhibitor treatment of the STR/Ort mouse corrected gait asymmetry and improved treadmill completion rates, whilst suppressing weight gain and serum OA biomarkers. Histological analyses of STR/Ort mouse knee joints revealed that in vivo CDK8/19-inhibitor treatment upregulated chondromodulin-1, matrillin-3 and enhanced proteoglycan deposition in the pericellular matrix of growth plate/articular cartilage. Micro computed tomography (µCT) showed that CDK8/19-inhibitor treatment modified chondrocyte endochondral behaviours to limit the number and density of mineralised growth plate bridges, which otherwise accumulate with age in STR/Ort mice. Collectively, these data highlight CDK8/19 inhibition as a promising disease-modifying strategy for targeting whole-joint disease in OA and, for the first time, show that CDK8/19 inhibition exerts pivotal control of multiple cellular processes that are crucial to endochondral ossification/OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.